1. Home
  2. TBPH vs GCMG Comparison

TBPH vs GCMG Comparison

Compare TBPH & GCMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • GCMG
  • Stock Information
  • Founded
  • TBPH 2013
  • GCMG 1971
  • Country
  • TBPH United States
  • GCMG United States
  • Employees
  • TBPH N/A
  • GCMG N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • GCMG Finance/Investors Services
  • Sector
  • TBPH Health Care
  • GCMG Finance
  • Exchange
  • TBPH Nasdaq
  • GCMG Nasdaq
  • Market Cap
  • TBPH 485.8M
  • GCMG 577.4M
  • IPO Year
  • TBPH N/A
  • GCMG N/A
  • Fundamental
  • Price
  • TBPH $9.15
  • GCMG $13.28
  • Analyst Decision
  • TBPH Buy
  • GCMG Hold
  • Analyst Count
  • TBPH 4
  • GCMG 5
  • Target Price
  • TBPH $13.75
  • GCMG $13.70
  • AVG Volume (30 Days)
  • TBPH 166.7K
  • GCMG 317.0K
  • Earning Date
  • TBPH 02-24-2025
  • GCMG 02-11-2025
  • Dividend Yield
  • TBPH N/A
  • GCMG 3.34%
  • EPS Growth
  • TBPH N/A
  • GCMG N/A
  • EPS
  • TBPH N/A
  • GCMG N/A
  • Revenue
  • TBPH $63,192,000.00
  • GCMG $462,593,000.00
  • Revenue This Year
  • TBPH $11.41
  • GCMG $16.86
  • Revenue Next Year
  • TBPH $37.36
  • GCMG $12.95
  • P/E Ratio
  • TBPH N/A
  • GCMG N/A
  • Revenue Growth
  • TBPH 15.93
  • GCMG 8.20
  • 52 Week Low
  • TBPH $7.44
  • GCMG $8.05
  • 52 Week High
  • TBPH $10.44
  • GCMG $13.24
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 49.84
  • GCMG 70.20
  • Support Level
  • TBPH $8.35
  • GCMG $12.66
  • Resistance Level
  • TBPH $8.86
  • GCMG $13.05
  • Average True Range (ATR)
  • TBPH 0.29
  • GCMG 0.30
  • MACD
  • TBPH -0.05
  • GCMG 0.06
  • Stochastic Oscillator
  • TBPH 58.39
  • GCMG 97.67

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About GCMG GCM Grosvenor Inc.

GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.

Share on Social Networks: